Daniel Schneider
Chief Executive Officer bij PHOTOCURE ASA
Vermogen: 508 182 $ op 31-03-2024
Profiel
Daniel Schneider is currently the President & Chief Executive Officer at Photocure ASA since 2018.
Prior to this, he worked as the General Manager at Ablynx NV.
He holds an MBA from the University of Washington and an undergraduate degree from St. Louis University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
PHOTOCURE ASA
0.37% | 31-12-2022 | 99 689 ( 0.37% ) | 508 182 $ | 31-03-2024 |
Actieve functies van Daniel Schneider
| Bedrijven | Functie | Begin |
|---|---|---|
| PHOTOCURE ASA | Chief Executive Officer | 01-11-2018 |
Eerdere bekende functies van Daniel Schneider
| Bedrijven | Functie | Einde |
|---|---|---|
| ABLYNX | Chief Executive Officer | - |
Opleiding van Daniel Schneider
| University of Washington | Masters Business Admin |
| St. Louis University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| PHOTOCURE ASA | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Ablynx NV
 Ablynx NV BiotechnologyHealth Technology Ablynx NV operates as a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand. It includes haematology, inflammation, infectious disease, autoimmune disease, oncology and immune-oncology. The company was founded by Mark Vaeck in 2001 and is headquartered in Ghent, Belgium. | Health Technology |
